Cargando…
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631657/ https://www.ncbi.nlm.nih.gov/pubmed/35790100 http://dx.doi.org/10.1182/bloodadvances.2022007782 |
| _version_ | 1784823861824454656 |
|---|---|
| author | Alderuccio, Juan P. Ai, Weiyun Z. Radford, John Solh, Melhem Ardeshna, Kirit M. Lunning, Matthew A. Hess, Brian T. Zinzani, Pier L. Stathis, Anastasios Carlo-Stella, Carmelo Hamadani, Mehdi Kahl, Brad S. Ungar, David Kilavuz, Turk Yu, Eric Qin, Yajuan Caimi, Paolo F. |
| author_facet | Alderuccio, Juan P. Ai, Weiyun Z. Radford, John Solh, Melhem Ardeshna, Kirit M. Lunning, Matthew A. Hess, Brian T. Zinzani, Pier L. Stathis, Anastasios Carlo-Stella, Carmelo Hamadani, Mehdi Kahl, Brad S. Ungar, David Kilavuz, Turk Yu, Eric Qin, Yajuan Caimi, Paolo F. |
| author_sort | Alderuccio, Juan P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9631657 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96316572022-11-04 Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study Alderuccio, Juan P. Ai, Weiyun Z. Radford, John Solh, Melhem Ardeshna, Kirit M. Lunning, Matthew A. Hess, Brian T. Zinzani, Pier L. Stathis, Anastasios Carlo-Stella, Carmelo Hamadani, Mehdi Kahl, Brad S. Ungar, David Kilavuz, Turk Yu, Eric Qin, Yajuan Caimi, Paolo F. Blood Adv Research Letter American Society of Hematology 2022-08-16 /pmc/articles/PMC9631657/ /pubmed/35790100 http://dx.doi.org/10.1182/bloodadvances.2022007782 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Research Letter Alderuccio, Juan P. Ai, Weiyun Z. Radford, John Solh, Melhem Ardeshna, Kirit M. Lunning, Matthew A. Hess, Brian T. Zinzani, Pier L. Stathis, Anastasios Carlo-Stella, Carmelo Hamadani, Mehdi Kahl, Brad S. Ungar, David Kilavuz, Turk Yu, Eric Qin, Yajuan Caimi, Paolo F. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study |
| title | Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study |
| title_full | Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study |
| title_fullStr | Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study |
| title_full_unstemmed | Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study |
| title_short | Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study |
| title_sort | loncastuximab tesirine in relapsed/refractory high-grade b-cell lymphoma: a subgroup analysis from the lotis-2 study |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631657/ https://www.ncbi.nlm.nih.gov/pubmed/35790100 http://dx.doi.org/10.1182/bloodadvances.2022007782 |
| work_keys_str_mv | AT alderucciojuanp loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT aiweiyunz loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT radfordjohn loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT solhmelhem loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT ardeshnakiritm loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT lunningmatthewa loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT hessbriant loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT zinzanipierl loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT stathisanastasios loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT carlostellacarmelo loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT hamadanimehdi loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT kahlbrads loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT ungardavid loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT kilavuzturk loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT yueric loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT qinyajuan loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study AT caimipaolof loncastuximabtesirineinrelapsedrefractoryhighgradebcelllymphomaasubgroupanalysisfromthelotis2study |